Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models

Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection.

(2017) J. Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.

(2017) B. Y. Karlan et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of the Pharmacokinetics of Romiplostim in Rodents with a Focus on the Clearance Mechanism

(2011) Yow-Ming C. Wang et al.   PHARMACEUTICAL RESEARCH

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Identification and inhibition of drug target interference in immunogenicity assays

(2010) Zhandong D. Zhong et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Identification of IgG1 variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: Comparison of soluble receptor-based and cell-based binding assays

(2010) Yanmei Lu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective

(2009) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal FcRn Reclaims Albumin but Facilitates Elimination of IgG

(2009) M. Sarav et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice

(2009) Héctor Pérez Montoyo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy

(2008) T.-Y. Lee et al.   CLINICAL CANCER RESEARCH

Podocytes use FcRn to clear IgG from the glomerular basement membrane

(2008) S. Akilesh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA